GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says
GSK's hepatitis B drug, Hibsago, received US approval, supporting Jefferies' £2.2bn sales forecast. Analysts maintain a 'buy' rating with a 2,500p target, citing 20% functional-cure rates. However, safety warnings and monitoring requirements may impact commercial rollout.
How this was made
The 30-second read
Why it matters
The approval removes a major regulatory hurdle, enabling GSK to launch the product and pursue its £2.2bn sales target, which could boost earnings and share price.
Market read
First‑report FDA approval for a high‑impact hepatitis B therapy, likely to drive GSK stock higher and influence biotech sector sentiment.
What to watch
Potential competition from emerging gene‑editing therapies and payer reimbursement challenges.
Background
GSK's hepatitis B treatment Hibsago (bepirovirsen) received its first US regulatory approval, a milestone for the company's infectious‑disease portfolio.
Ticker impact
US FDA approval of GSK's hepatitis B drug Hibsago supports a £2.2bn sales forecast.
upward pressure as investors price in potential peak sales.
The drug targets a large patient pool and analysts project multi‑billion‑dollar revenue, prompting a buy rating and price target lift.
Market effects
Strengthens the broader pharma/biotech sector's outlook on antiviral pipelines.
Positive for UK‑listed pharma and US‑listed ADRs with similar therapeutic focus.
Adds to global healthcare innovation narrative, may influence biotech indices.
Counterpoint
Safety warnings and intensive monitoring could limit adoption and dampen upside.
Key entities
- companyGSK PLC
British pharmaceutical giant, US‑listed as GSK.
- regulatorFDA
U.S. Food and Drug Administration, granted approval for Hibsago.
